Combined effect of hydroxypropyl-β-cyclodextrin and media pH on the solubility of prostaglandin E1

Abstract

Abstract: Aim To investigate the combined effect of hydroxypropyl-β-cyclodextrin (HP-β-CD) and media pH on the solubility of prostaglandin E1 (PGE1) and construct a theoretical equation for the drug solubility as a function of HP-β-CD concentration and media pH. Methods The solubility of PGE1 under different pH conditions was determined. Then, the drug solubility in different concentrations of HP-β-CD acidic or pH neutral solutions was measured, respectively. Finally, a theoretical solubility equation for the drug as a function of HP-β-CD concentration and media pH was deduced and confirmed in experiment. Results PGE1 was solubilized by HP-β-CD or by increasing media pH. The drug solubility as a function of HP-β-CD concentration was found to follow the AL-type complexation model in acidic or neutral pH media, suggesting that both the ionized and neutral drugs form 1:1 molecular ratio complexes. Conclusions The solubility of PGE1 may be improved by increasing media pH or by using HP-β-CD as a solubilizer. HP-β-CD and media pH can produce combined effect on the solubility of PGE1. The deduced equation for the drug solubility in this study effectively characterizes the roles of HP-β-CD and media pH in determining total solubility of the drug.

Key words: PGE1, PGE1, HP-β-CD, HP-β-CD, pH, pH, Solubility, Solubility, Complexation, Complexation, Theoretical equation, Theoretical equation

CLC Number:

R911.1

Supporting:

Fu-Gen Gu^*, Chun-Zhi Wu, Yong-Liang Gao. Combined effect of hydroxypropyl-β-cyclodextrin and media pH on the solubility of prostaglandin E₁[J]. .

References

[1] Yamamoto M, Hirayama F, Uekama K. Improvement ofstability and dissolution of prostaglandin E1 by maltosyl-β-cyclodextrin in lyphilized formulation [J]. Chem PharmBull, 1992, 40: 747–751.
[2] Cawello W, Schweer H, Müller R, et al. Metabolism andpharmcokinetics of prostaglandin E1 administered byintravenous infusion in human subjects [J]. Eur J ClinPharmacol, 1994, 46: 275–277.
[3] Cawello W, Leonhardt A, Schweer H, et al. Dose proportionalpharmacokinetics of alprostadil (prostaglandin E1)in healthy volunteers following intravenous infusion [J].Br J Clin Pharmacol, 1995, 40: 273–276.
[4] Wang H. Clinical applications of alprostadil [J]. TianjinPharm, 2002, 14: 20–21.
[5] Yang ZH, Chen YQ, Yang GC. Advance in clinical applicationsof prostaglandin E1 [J]. Chin Pharm, 2001, 10: 52.
[6] Hirayama F, Kurihara M, Uekama K. Mechanisms of decelerationby methylated cyclodextrins in the dehydrationof prostaglandin E2 and the isomerization of prostaglandinA2 in aqueous solution [J]. Chem Pharm Bull, 1986, 34: 5093–5101.
[7] Carpenter TO, Gerloczy A, Pitha J. Safety of parenteralhydroxypropyl-β-cyclodextrin [J]. J Pharm Sci, 1995, 84: 222–225.
[8] Loftsson T, Brewster ME. Pharmaceutical applications ofcyclodextrins, 1. drug solubilization and stabilization [J].J Pharm Sci, 1996, 85: 1017–1025.
[9] Adachi H, Irie T, Hirayama F, et al. Stabilization of prostaglandinE1 in fatty alcohol propylene glycol ointment byacidic cyclodextrin derivative, O-caroxymethyl-O-ethyl-β-cyclodextrin [J]. Chem Pharm Bull, 1992, 40: 1586–1591.
[10] Gu FG, Cui FD, Gao YL. Effect of complexation withhydroxylpropyl-β-cyclodextrin on the solubility, dissolutionrate and chemical stability of prostaglandin E1 [J].Chin Pharm Sci, 2004, 13 (3): 158–165.
[11] Teagarden DL, Anderson BD, Petre WJ. Dehydration kineticsof prostaglandin E1 in a lipid emulsion [J]. PharmRes, 1989, 6: 210–215.
[12] Higuchi T, Connors KA. Phase solubility techniques [J].Adv Anal Chem Instrum, 1965, 4: 117–212.

[1]	Mengyao Wu, Lu Liu, Peng Zhang, Lele Zhang, Yun Gong, Xiuwei Yang. Exploring the mechanism of Buxue Yimu Pills on postpartum abdominal pain through network pharmacology and experimental validation [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 691-703.
[2]	Ping Shang, Lin Liu, Yi Fang. Investigating the mechanism of action of Gui Zhi Fu Ling Wan in the treatment of endometriosis based on network pharmacology and molecular docking [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 704-719.
[3]	Gedi Zhang, Gengxin Liu, Ziyou Yan. Therapeutic efficacy evaluation and mechanism of action based on meta-analysis and network pharmacology of Li Chong Decoction (Bolus) for cancer treatment [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(9): 720-735.
[4]	Wen Lv, Ying Fu. Advances in immune-targeted therapy for Graves' ophthalmopathy [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(8): 616-625.
[5]	Jie Yang, Caifang Jing, Shaochuang Li, Sitong Liu, Dongming Li, Qinqing Li, Wenbin He. Preparation optimiztion of compound Codonopsis Radix granules and simultaneous determination of its four components [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(8): 665-676.
[6]	Weiwei Xie, Jian Liu, Yuqian Zhang, Zhiqing Zhang, Yiran Jin. A case of anaphylactic shock caused by iodixanol during transjugular intrahepatic portosystemic shunt and literature analysis [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(8): 677-682.
[7]	Dongyan Wu, Xiaodan Wang, Jinmiao Chai, Qinqing Li, Yue Li, Mei Bi, Wanwei Gui, Huimin Cao. Study on the mechanism of Danggui Buxue decoction in the treatment of diabetic retinopathy based on network pharmacology and experiment [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(7): 527-538.
[8]	Yanfang Yang, Wei Wei, Lei Zhang, Wei Xu, Xiuwei Yang. Simultaneous quantification of 37 constituents in Duliang Pill by UPLC-MS/MS: Application to the pharmacokinetic studies in rat plasma [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(7): 560-573.
[9]	Yancong Zhao, Li Wang, Jingjing Zeng, Jinghua Li. The structure and antiproliferative activity of the inclusion complex of neoandrographolide/β-cyclodextrin [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(6): 427-434.
[10]	Huan Yan, Jian Wang, Hao Fu, Min Yang, Miao Qu, Zhie Fang. Discussion on the potential target and mechanism of Dachaihu Decoction in treating hyperlipidemia based on network pharmacology [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(6): 446-459.
[11]	Han Wang, Fanglong Li, Aga Er-bu, Xiaoxia Liang, Geng Sang, Car Rangnanjia. The in vitro antioxidant activities of the ethanol extract and its different polar fractions from Ephedra saxatilis Royle ex Florin in Tibet [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(6): 478-486.
[12]	Mengya Wang, Kuanyou Zhang, Xin Chen, Hao Fu, Shouchun Peng. Study on the mechanism of Rhinoceros Horn and Rehmannia Decoction in the treatment of systemic lupus erythematosus based on the method of network pharmacology [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(5): 351-359.
[13]	Guangzhi Shen, Xingang Cui, Zhimin Na, Yulong Zou, Guihua Zou. A network pharmacology approach to explore the pharmacological mechanism of Epimedium brevicornum in sexual dysfunction [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(5): 379-391.
[14]	Yonghui Ge, Ling Wang, Su Xu, Tianli Jiang, Jinhua Wang. Direct identification of volatile compounds in the artificially cultivated and wild Chinese medicinal materials (Semiliquidambar cathayesis) by headspace-gas chromatography-ion mobility spectrometry [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(5): 392-405.
[15]	Min Ao, Minglan Bao, Yaxing Hou, Ying Yue, Huifang Li, Guohua Wu, Su Ri Ga La Tu. Study on the mechanism of Mongolian medicine Herba Lomatognii against acute liver injury based on network pharmacology [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(4): 268-282.

Combined effect of hydroxypropyl-β-cyclodextrin and media pH on the solubility of prostaglandin E₁

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments